Lisata Therapeutics (NASDAQ:LSTA) Given “Buy” Rating at HC Wainwright

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 432.86% from the company’s previous close.

Lisata Therapeutics Trading Up 6.6 %

NASDAQ LSTA opened at $2.82 on Wednesday. The company has a fifty day simple moving average of $2.88 and a 200 day simple moving average of $3.08. Lisata Therapeutics has a 12-month low of $2.19 and a 12-month high of $3.83. The company has a market cap of $23.63 million, a P/E ratio of -1.12 and a beta of 1.16.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.16. During the same quarter in the prior year, the company earned ($0.65) EPS. Sell-side analysts predict that Lisata Therapeutics will post -2.66 EPS for the current year.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP grew its stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 17,336 shares of the company’s stock after acquiring an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.